Approval for Pfizer, Moderna Covid-19 vaccines under consideration: Govt
Premium
(HT PRINT)
Read Full Story
The central government is in discussions with American pharmaceutical companies Pfizer and Moderna over their Covid-19 vaccines, said Dr VK Paul, member (health) of Niti Aayog. Approval to Pfizer and Moderna is under consideration, Paul said.
MORE FROM THIS SECTIONSee All
Premium Premium
Premium Premium
Premium Premium
Premium Premium
He informed that Pfizer has indicated its vaccines will likely be available in July.
This comes a day after government officials stated that if India enters into procurement deals with Pfizer, Moderna and J&J, then the vaccine supply will be further boosted. This will help the country realise its target of inoculating all adults by the end of the year.
Battling the world s biggest jump in coronavirus infections, India halted vaccine exports a month ago after donating or selling more than 66 million doses
Timeline Of Russian Sputnik V Covid-19 Vaccine, Approved For Emergency Use In India
by Bhaswati Guha Majumder - Apr 13, 2021 03:55 PM
Russian Covid-19 vaccine Sputnik V
Snapshot
A quick look at the journey of Russian Covid-19 vaccine Sputnik V, from its early days till its entry in India.
Russia s Covid-19 vaccine is the worldâs first to be registered based on the human adenoviral vector-based platform.
Now, India has become the sixtieth country to approve the two-dose Sputnik V vaccine after the Drugs Controller General of India (DCGI) gave the green signal.
Here is the journey of Sputnik V and its entry into India.
Overcoming formidable biological and sociocultural barriers, India eliminated wild polioviruses from its territory in January 2011. Looking back, it is obvious that the best policy would have been to introduce the inactivated poliovirus vaccine to prevent polio in every vaccinated child, and to use oral poliovirus vaccine by pulse campaigns to eliminate WPVs rapidly. This would have eliminated polio decades ago. Now that WPVs have been eliminated, IPV must be introduced as a prelude to withdrawing OPV. The road ahead is bumpy, but with the important lessons learnt so far, India can no longer pretend that it is too difficult to design a permanent public health infrastructure to control other communicable and non-communicable diseases.
Story highlights
Pfizer in its application submitted to the drug regulator in December 2020, had sought permission to import the vaccine for sale and distribution in India, besides waiver of clinical trials on Indian population.
Pharma major Pfizer on Friday said it has decided to withdraw its application for Emergency Use Authorisation (EUA) of its COVID-19 vaccine in India.
Pfizer was the first pharmaceutical firm to seek an emergency use authorisation from the Drugs Controller General of India (DCGI) for its COVID-19 vaccine in the country, after it secured such clearance in the UK and Bahrain. In pursuance of the Emergency Use Authorisation of its COVID-19 vaccine, Pfizer participated in the Subject Expert Committee meeting of the Drug Regulatory Authority of India on February 3. Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time, a company sp